Last reviewed · How we verify
Ixabepilone, 25 mg, with famotidine
Ixabepilone, 25 mg, with famotidine is a Small molecule drug developed by R-Pharm. It is currently in Phase 1 development.
At a glance
| Generic name | Ixabepilone, 25 mg, with famotidine |
|---|---|
| Sponsor | R-Pharm |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ixabepilone, 25 mg, with famotidine CI brief — competitive landscape report
- Ixabepilone, 25 mg, with famotidine updates RSS · CI watch RSS
- R-Pharm portfolio CI
Frequently asked questions about Ixabepilone, 25 mg, with famotidine
What is Ixabepilone, 25 mg, with famotidine?
Ixabepilone, 25 mg, with famotidine is a Small molecule drug developed by R-Pharm.
Who makes Ixabepilone, 25 mg, with famotidine?
Ixabepilone, 25 mg, with famotidine is developed by R-Pharm (see full R-Pharm pipeline at /company/r-pharm).
What development phase is Ixabepilone, 25 mg, with famotidine in?
Ixabepilone, 25 mg, with famotidine is in Phase 1.
Related
- Manufacturer: R-Pharm — full pipeline
- Compare: Ixabepilone, 25 mg, with famotidine vs similar drugs
- Pricing: Ixabepilone, 25 mg, with famotidine cost, discount & access